Gesynta Pharma has been awarded a Vinnova grant to develop an environmentally friendly method for producing our drug candidate, vipoglanstat.

 Led by our project leader Maths Nilsson and carried out in collaboration with RISE, the project “Removing chlorinated solvents from drug candidate manufacturing process” demonstrates our commitment to pioneering innovative solutions in pharmaceutical manufacturing without compromising safety or quality.

 We're thrilled to contribute to sustainable development in the pharmaceutical industry together with Sweden's innovation agency Vinnova and Sweden's research institute and innovation partner RISE. Gesynta Pharma embraces and supports the UN Sustainable Development Goals (SDGs).

 Gesynta Pharma is dedicated to the development of better treatments for endometriosis patients, with promising preclinical data for vipoglanstat and a clinical phase II study coming.

 Learn more about the UN Sustainable Development Goals: https://sdgs.un.org/goals